3. ACADIA Pharmaceuticals, Inc. ( ACAD): Focuses on drug discovery and clinical development of novel treatments for central nervous system disorders.

Market cap at $1.755B, most recent closing price at $20.89.

Over the last six months, insiders were net buyers of 3,964,834 shares, which represents about 8.04% of the company's 49.34M share float.

ACADIA Pharmaceuticals has returned -23.80% since October 7 th, falling considerably behind several industry peers including Gilead Sciences and Amgen, which returned 9.05% and 2.82% during the same time period.

In the pipeline:

During the company's third quarter earnings call, CEO Uli Hacksell stated that ACADIA is on track to submit a new drug application for its pimavanserin medication - specifically for the treatment of Parkinson's disease psychosis (PDP) – to the FDA near the end of 2014.

Pimavanserin is also in clinical trials for the treatment of schizophrenia and Alzheimer's disease psychosis; ACADIA completed its Phase 2 trial for schizophrenia last year and will commence the Phase 2 trial for Alzheimer's disease psychosis (ADP) this month. Currently no drugs have been approved for the treatment of either PDP or ADP in the US.

 

 

( List compiled by Mary-Lynn Cesar, a Kapitall Writer. Insider data sourced from Yahoo! Finance. Analyst ratings data sourced from Zacks Investment Research. All other data sourced from Finviz)

null

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon